Close

Auris Medical Holding (EARS) Says it Resumed Enrollment in TACTT3 Phase 3 Trial of Keyzilen

January 26, 2017 8:11 AM EST Send to a Friend
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login